MP07-66

• Description:

  MP07-66, a FTY720 analogue, is devoid of immunosuppressive effects and shows promising antitumor effects in chronic lymphocytic leukemia by disruption of the SET-PP2A complex leading to PP2A reactivation[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  Phosphatase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mp07-66.html

• Purity:

  99.86

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  CCCCCCOC1=CC=C(CNCC(OCC)OCC)C=C1

• Molecular Formula:

  C19H33NO3

• Molecular Weight:

  323.47

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Zonta F, et al. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood. 2015;125 (24) :3747-3755.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1938056-90-6]